Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

Nature

Volumn 515, Issue 7528, 2014, Pages 572-576

  Yadav, Mahesh ^a   Jhunjhunwala, Suchit ^a   Phung, Qui T ^a   Lupardus, Patrick ^a   Tanguay, Joshua ^a   Bumbaca, Stephanie ^a   Franci, Christian ^a   Cheung, Tommy K ^a   Fritsche, Jens ^b   Weinschenk, Toni ^b   Modrusan, Zora ^a   Mellman, Ira ^a   Lill, Jennie R ^a   Delamarre, Lélia ^a  

^a GENENTECH INC   (United States)

^b IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; T LYMPHOCYTE RECEPTOR; TRANSCRIPTOME; CANCER VACCINE; PEPTIDE;

CANCER; CELL ORGANELLE; IMMUNE SYSTEM; MASS SPECTROMETRY; MOLECULAR ANALYSIS; MONITORING; MUTATION; PEPTIDE; REACTION KINETICS; RODENT; SOLVENT; TUMOR; VACCINATION;

ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXOME; FEMALE; GENE SEQUENCE; IMMUNOGENICITY; MASS SPECTROMETRY; MOUSE; MUTATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MODEL; VACCINATION; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; IMMUNOPRECIPITATION; NEOPLASM; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

MUS;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EXOME; FEMALE; GENE EXPRESSION PROFILING; IMMUNITY, CELLULAR; IMMUNOGENETIC PHENOMENA; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY;

EID: 84920956731     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14001     Document Type: Article

References (38)

1. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
2. Matsushita, H. et al.Cancer exome analysis reveals a T-cell-dependentmechanism of cancer immunoediting. Nature 482, 400-404 (2012).
3. DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405-409 (2012).
4. Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081-1091 (2012).
5. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
6. Gros, A. et al. PD-1 identifies the patient-specific CD81 tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246-2259 (2014).
7. Tran, E. et al.Cancerimmunotherapy based onmutation-specificCD41T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
8. Wick, D. A. et al. Surveillance of the tumormutanomeby T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 20, 1125-1134 (2014).
9. Brown, S. D. et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24, 743-750 (2014).
10. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10 (2013).
11. Lundegaard, C. et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509-W512 (2008).
12. Gujar, S. A., Pan, D. A.,Marcato, P., Garant, K. A. & Lee, P. W. Oncolytic virus-initiated protective immunity against prostate cancer. Mol. Ther. 19, 797-804 (2011).
13. Fortier, M. H. et al. The MHC class I peptide repertoire is molded by the transcriptome. J. Exp. Med. 205, 595-610 (2008).
14. Granados, D. P. et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood 119, e181-e191 (2012).
15. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genet. 44, 685-689 (2012).
16. Bertsch, E. et al.MED12andHMGA2mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod. Pathol. 27, 1144-1153 (2014).
17. Goldberg, A. L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans. 35, 12-17 (2007).
18. Sette, A. et al. Therelationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
19. London, N., Raveh, B., Cohen, E., Fathi, G. & Schueler-Furman, O. Rosetta FlexPepDock web server-high resolution modeling of peptide-protein interactions. Nucleic Acids Res. 39, W249-W253 (2011).
20. Rudolph, M. G., Stanfield, R. L. & Wilson, I. A. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24, 419-466 (2006).
21. Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733-14738 (2010).
22. Jin, H. T., Ahmed, R. & Okazaki, T. Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 350, 17-37 (2011).
23. Wherry, E. J. T cell exhaustion. Nature Immunol. 12, 492-499 (2011).
24. Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specificCD81T cell dysfunction in melanoma patients. J. Exp.Med. 207, 2175-2186 (2010).
25. Fourcade, J. et al. CD81 T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887-896 (2012).
26. Crespo, J., Sun, H., Welling, T. H., Tian, Z. & Zou, W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25, 214-221 (2013).
27. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991).
28. Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873-881 (2010).
29. Wu, T. D.&Watanabe, C. K.GMAP: a genomicmapping and alignment programfor mRNA and EST sequences. Bioinformatics 21, 1859-1875 (2005).
30. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet. 43, 491-498 (2011).
31. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069-2070 (2010).
32. Butler, N. S. et al. Structural and biological basis of CTL escape in coronavirusinfected mice. J. Immunol. 180, 3926-3937 (2008).
33. Young, A. C., Zhang, W., Sacchettini, J. C.& Nathenson, S. G. The three-dimensional structure of H-2Db at 2.4Åresolution: implications for antigen-determinant selection. Cell 76, 39-50 (1994).
34. Denton, A. E. et al. Affinity thresholds for naive CD81 CTL activation by peptides and engineered influenza A viruses. J. Immunol. 187, 5733-5744 (2011).
35. Ostrov, D. A. et al.HowH13histocompatibility peptides differing by a singlemethyl group and lacking conventional MHC binding anchor motifs determine selfnonself discrimination. J. Immunol. 168, 283-289 (2002).
36. Wang, B. et al. Peptidic termini play a significant role in TCR recognition. J. Immunol. 169, 3137-3145 (2002).
37. Zhao, R., Loftus, D. J., Appella, E. & Collins, E. J. Structural evidence of T cell xeno-reactivity in the absence of molecular mimicry. J. Exp. Med. 189, 359-370 (1999).
38. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).